Trial document





This study has been imported from ClinicalTrials.gov without additional data checks.
drksid header

  DRKS00008805

Trial Description

start of 1:1-Block title

Title

A Randomised Controlled Double-Blind Clinical Study To Evaluate The Safety And Performance Of Neuromuscular Electrical Stimulation (NMES) With The Neurotech Vital Device For The Treatment Of Stress Urinary Incontinence

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

[---]*

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

Stress Urinary Incontinence (SUI) is described as an uncontrolled loss of urine which
happens when physical activities such as running, jumping and lifting etc are carried out or
when increased pressure to the bladder in everyday life is applied by simply sneezing or
coughing.

There are various treatment options available - surgical operations, pelvic floor
exercises/muscle training and electrical stimulation. This study aims to prove that using
the Neurotech Vital device for 12 weeks can stimulate the pelvic floor muscles to strengthen
and tone them and in doing so improving stress urinary incontinence. We are comparing the
Neurotech Vital device with an altered Neurotech Vital device that does not give the same
stimulation treatment. There is a 50% chance of you receiving the altered device, if you do,
you will be offered the non-altered Neurotech vital device after your first 12 week
treatment programme. Both devices are identical in looks, but give different stimulations
through the skin contact electrodes.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

The study involves wearing a device that includes a wired garment around the hip and bottom
area for a period of 30 minutes, 5 days out of 7, for 12 weeks. During this treatment,
electrical stimulation is passed through skin contact electrodes (large sticky black pads)
which causes the pelvic floor to contract and relax, without you having to do anything. This
treatment is not painful and is very similar to the workout you would get from relaxing and
contracting your pelvic floor muscles yourself, however the device produces a much stronger
contraction.

The study is open to females who have failed a 6 week exercise programme and have been
diagnosed with Stress Urinary Incontinence. It will take place at hospital uro-gynaecology
clinics/continence clinics across the United Kingdom. The study could last up to 16 months.

This study is being carried out to further prove that the Neurotech Vital device is an
effective way of treating stress urinary incontinence in female participants.The study will
look at the results of a 12 week treatment programme with the Neurotech Vital device
compared to the modified Neurotech Vital device. It will compare the following:

1. how much urine is lost in a standard 1 minute stress test carried out at the baseline
visit (start of the treatment) right through to visit 5 (end of the treatment - 12
weeks).

2. How much improvement is shown in the quality of life questionnaire (this is measured by
ticking questions which have scores attached to them and adding up the total score for
the questionnaire). This questionnaire asks questions on quality of life which is
affected by stress urinary incontinence.

end of 1:1-Block scientific synopsis
start of 1:1-Block forwarded Data

Do you plan to share individual participant data with other researchers?

[---]*

end of 1:1-Block forwarded Data
start of 1:1-Block forwarded Data Content

Description IPD sharing plan:

[---]*

end of 1:1-Block forwarded Data Content
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00008805
  •   2015/06/25
  •   2013/09/04
  •   no
  •   [---]*
  •   [---]*
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   NCT02214784  (ClinicalTrials.gov)
  •   BMR-11-1002  (Bio-Medical Research, Ltd.)
  •   ISRCTN68358784 
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   Stress Urinary Incontinence
  •   N39.3 -  Stress incontinence
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Device: Active Neurotech Vital
  •   Device: Modified Neurotech Vital Device
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Interventional
  •   [---]*
  •   Randomized controlled trial
  •   Blinded
  •   patient/subject, caregiver, investigator/therapist
  •   Placebo, Active control (effective treament of control group)
  •   Treatment
  •   Crossover
  •   II
  •   [---]*
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

- All participants taking part in a standardised 1-minute stress test; time frame: 12 weeks; We will look at the amount of urine in grams which is lost by participants when carrying out a stress test with all participants and compare their urine loss measured at baseline and then what it measures at 12 weeks after the 12 weeks treatment with the device. Comparing these against one another to look at any improvement.
- All participants to complete a Quality of life questionnaire (I-QOL); time frame: 12 weeks; We will look at the scores which are taken from these questionnaires (depending on which answer is ticked by the participant on the questionnaire) at baseline before treatment with the device commences and then again after 12 weeks of treatment with the device and compare the scores for any improvement.

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

- participants taking part in a 1 minute stress test; time frame: 4, 8, 12 and 26 weeks; We will look at the amount of urine in grams which is lost by participants when carrying out a stress test with all participants and compare their urine loss measured at 4, 8 and 12 weeks against each other and calculate any difference to ascertain if any improvment has been gained by following the device treatment schedule.
- participants taking part in a 1-hour pad weight test; time frame: Stress test done at 4, 8 and 12 weeks during treatment with the device and at 6 months, for the main and cohort part of study; The loss of urine in grams after this test at the above time points will be collected and using the definition of dryness (pad weight of less than 1 gram) they will be looked at to see if at any of the above timepoints the participants are classed as dry i.e. have urine loss of less than 1gram following the stres test.
- particpants taking part in the stress test and then having the pad weight to show loss of urine.; time frame: 4, 8 and 12 weeks and at 6 months for main and cohort part of the study; We are looking at a significant reduction in the weight of the pad after the stress test has taken place, this improvement is defined as a greater than 50% reduction in pad weight in all particpants who took the test at baseline compared to the weight of the pad at 4, 8 and 12 weeks and at 6months for the main and cohort studies.
- 1-hour pad weight test; time frame: 4, 8 and 12 weeks and at 6 months, for main and cohort part of the study; reduction in pad weight on the 1-hour pad weight test in relation to the mean intensity of the stimulation delivered during the 12-week treatment programme;
- quality of life questionnaire; time frame: 4, 8 and 12 weeks and at 6 months, for main part and cohort part of the study; quality of life assessed using the Incontinence Quality of Life Questionnaire (I-QOL) (except for the 12 week assessment which is one of the primary endpoints);
- quality of life questionnaire; time frame: 4, 8 and 12 weeks and at 6 months for main and cohort part of the study; quality of life questionnaire assessed using the Kings Health Questionnaire (KHQ)
- 24 hour pad weight test; time frame: 4, 8 and 12 weeks and at 6 months for main and cohort part of the study; urine leakage experienced by the subject at home during a 24-hour period (24-hour pad weight test);
- 24 hour pad weight test; time frame: 4, 8 and 12 weeks and at 6 months for main and cohort part of the study; dryness, defined as a pad weight of less than 1.3g on the 24-hour pad weight test;
- 24hour pad weight test; time frame: 4, 8 and 12 weeks and at 6 months for main and cohort part of the study; significant improvement, defined as a greater than 50% reduction in pad weight from baseline on the 24-hour pad weight test;
- 3-day diary card; time frame: 4, 8 and 12 weeks and at 6 months for main and cohort part of the study; number of incontinence episodes/day recorded using a 3-day voiding diary;
- 3-day voiding diary; time frame: 4, 8 and 12 weeks and at 6 months for main and cohort part of the study; number of pads used/day recorded using a 3-day voiding diary;
- Modified Oxford Score; time frame: 4, 8 and 12 weeks and at 6 months for main and cohort part of the study; pelvic floor strength and quality of contraction measured using the Modified Oxford Score;
- Pelvic floor ultrasound; time frame: 4, 8 and 12 weeks and at 6 months for main and cohort part of the study; pelvic floor muscle function measured using sonographic/real time ultrasound imaging/recording with displacement measurement using on screen callipers on the sonogram unit to assess volitional contractions
- participants taking part in a 1 minute stress test; time frame: We will compare the urine loss against the urine loss after 4weeks treatment with the device and also after 8weeks treatment with the device and 12 weeks treatment; We will look at the amount of urine in grams which is lost by participants when carrying out a stress test with all participants and compare their urine loss measured at 4, 8 and 12 weeks against each other and calculate any difference to ascertain if any improvment has been gained by following the device treatment schedule.

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  •  
  •  
  •  
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   [---]*
  •   2012/12/31
  •   140
  •   Multicenter trial
  •   National
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Female
  •   18   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

- Subjects who are female and at least 18 years of age.

- Subjects who have signed informed consent form prior to any study related activity.

- Subjects who have previously failed a 6 week volitional pelvic floor muscle training
programme or in the Investigators opinion an equivalent lifestyle and exercise
programme.

- Subjects who have been clinically diagnosed with stress urinary incontinence and
demonstrate a >4g urine leakage following a standardised 1-minute stress test at 1
hour post-bladder filling protocol (1-hour pad weight test). Stress urinary
incontinence is defined as complaint of involuntary leakage on effort or exertion, or
on sneezing and coughing' (International Continence Society).

- Subjects who have scored at least 18 out of 27 for the Stress Incontinence Questions
and are confirmed as having predominant stress urinary incontinence on the Medical,
Epidemiologic and Social Aspects of Aging Urinary Incontinence (MESA) Questionnaire
completed at the screening assessment.

- Subjects with a Body Mass Index of ≤ 40 kg/m2

- Subjects who are able to give voluntary, written informed consent to participate in
this study and from whom consent has been obtained.

- Subjects who are able to understand this study and are willing to complete all the
study assessments.

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

- Subjects who have an existing medical condition that would compromise their
participation in the study.

- Subjects who have a physical condition that would make them unable to perform the
study procedures.

- Subjects who have any respiratory condition including a chronic cough or history of
same.

- Subjects with a history of an underlying neurological condition.

- Subjects with a history of low back pain involving the spinal nerve root.

- Subjects who are currently taking medication, or have taken medication in the last 4
weeks, for urinary incontinence or that effect urinary output function including
anti-cholinergics or anti-histamines or any anti-anxiety medications.

- Subjects with a blood clotting disorder or who are taking anti-coagulant medications.

- Subjects who have previously had any uro-gynaecological related surgery excluding
hysterectomy.

- Subjects with a clinical diagnosis of prolapse greater than Stage 2.

- Subjects who are pregnant or could be pregnant.

- Subjects who are less than 6 months post-partum or who are lactating.

- Subjects who have any intra-uterine devices or metal implants in the pelvic area,
including hip and lumbar spine.

- Subjects with pelvic pain or fibromyalgia or paravaginal defect.

- Subjects with an active implanted medical device (i.e. pacemaker, pump etc).

- Subjects with a history of heart disease or stroke.

- Subjects with a known cancer.

- Subjects with an injury or disability affecting any part of their body which will be
in contact with the garment.

- Subjects who are currently involved in any injury litigation claims.

- Subjects who have participated in a clinical study in the last 3 months or any
previous clinical study with Bio-Medical Research Ltd.

- Subjects who have been committed to an institution by virtue of an order issued
either by the courts or by an authority.

- Any vulnerable subjects defined as individuals whose willingness to volunteer in a
clinical study may be unduly influenced by the expectation, whether justified or not,
of benefits associated with participation, or of a retaliatory response from senior
members of a hierarchy in case of refusal to participate. Examples are members of a
group with a hierarchical structure, such as medical, pharmacy, dental and nursing
students, subordinate hospital and laboratory personnel, employees of the
pharmaceutical and medical device industry, members of the armed forces, and persons
kept in detention. Other vulnerable subjects include patients with incurable
diseases, persons in nursing homes, unemployed or impoverished persons, patients in
emergency situations, ethnic minority groups, homeless persons, nomads, refugees,
minors, and those incapable of giving consent.

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • Bio-Medical Research, Ltd.
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • St Hedwig Krankenhaus, Berlin
    • R Tunn, Professor 
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Sheryl OFarrell, Dr 
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting ongoing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
The parameters in ClinicalTrials.gov and DRKS are not identical. Therefore the data import from ClinicalTrials.gov required adjustments. For full details please see the DRKS FAQs .
  •   2
  •   2016/01/14


* This entry means the parameter is not applicable or has not been set.